Chiesi USA Releases 2023 Sustainability Report and Highlights US Community Engagement Strategy Focus Areas
09 oct. 2024 07h30 HE
|
Chiesi USA, Inc.
2023 Sustainability Report demonstrates strong impact across Patients, Planet, People and ProsperityUS Community Engagement Strategy will address access to healthcare, food security, environmental...
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
16 mai 2024 08h00 HE
|
Chiesi USA, Inc.
Presentations will highlight new data in respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD)Data to be presented include new six-month results from a study of a...
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
15 avr. 2024 08h00 HE
|
Chiesi USA, Inc.
Richard Smith brings 25 years of expertise in building commercial excellence and partnering with the healthcare community across multiple therapeutic areasChiesi USA remains steadfast in its...
Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023
08 août 2023 09h00 HE
|
Chiesi USA, Inc.
Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed by the U.S. and ChinaForecasted revenues of...
Chiesi USA CEO Appointed to ASHP Foundation Board of Directors
20 juil. 2023 09h00 HE
|
Chiesi USA, Inc.
CARY, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Jon Zwinski, CEO and General Manager at Chiesi USA,...
Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer
12 juin 2023 09h00 HE
|
Chiesi USA, Inc.
CARY, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, in partnership with Smith Anderson, a Triangle-based full-service business...
2022 for Chiesi: The Group’s international growth continues
11 avr. 2023 09h00 HE
|
Chiesi USA, Inc.
Turnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic area...
Chiesi USA donates more than $830,000 to local communities and nonprofits in 2022
28 mars 2023 09h00 HE
|
Chiesi USA, Inc.
Chiesi’s CSR initiative, Chiesi in the Community, was determined to out-do itself in another year of meaningful community impact.2022 efforts include deepened partnerships with Triangle-area...
Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention
02 déc. 2022 09h00 HE
|
Chiesi USA, Inc.
As a Certified B Corporation™, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals. CARY, N.C.,...
Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome
29 nov. 2022 09h00 HE
|
Chiesi USA, Inc.
This cost-consequence analysis suggests selective early rescue surfactant administration strategies are associated with a lower healthcare burden in premature infants with RDS. CARY, N.C., Nov. ...